HD-OPM Archive
Topics › Plaque, CAC & CT angiography

YELLOW-III reversed total atheroma volume 4.4% in 6 months at LDL of about 39 mg/dL

Louis Nervegna · Mar 23, 2026 · ♥ 7 reactions · 6 comments · original Facebook post
Plaque, CAC & CT angiographyPCSK9, ezetimibe & newer drugsStatins
AI summary & key facts

Louis adds a green dot for YELLOW-III to his plaque-reversal chart. High-dose statin plus a PCSK9 inhibitor reduced total atheroma volume from 137.2 to about 131 mm3 in only 6 months and stabilized plaque, with post-treatment LDL averaging 39.1 mg/dL.

I added a green dot to this chart, so people can see how the plaque reversal in the recent YELLOW-III trial compares to previous trials.

As a reminder, YELLOW-III used high dose statins plus the addition of a PCSK9 inhibitor.

The details of the trial were described in these previous posts:

↪ YELLOW-III: statin plus evolocumab thickened fibrous caps over 30% in 6 months

facebook.com/share/v/1ET5kJQdpM

For a description of this chart, see this previous post:

↪ Plaque volume begins to regress once LDL-C falls below about 90 mg/dL across RCTs

While not as large as some of the other trials… keep in mind that this reversal happened in only 6 months! It was also accompanied by a significant stabilization of existing plaque.

Here is the math on how the green dot was calculated:

The starting total atheroma volume (TAV) in this trial was 137.2 mm^3. The decrease in TAV was -6.0 mm^3. So the percent decrease in TAV was -6.0 / 137.2 = -4.4%. This sets the location on the y-axis.

The average LDL in this trial (after treatment) was 39.1 mg/dL, or roughly 1 mmol/L. This sets the location on the x-axis.

#reverseHD #statinreverseHD #pcsk9reverseHD #tavHD #plaqueHD #ivusHD #lipidcoreHD #statinsHD #pcsk9HD #yellowiiiHD #meltingbuttersignHD

Research cited

← newer: PD-STAT: simvastatin did not slow Parkinson's progression inolder: Closer MIND diet adherence linked to slower structural brain →